New Zealand markets open in 3 hours 32 minutes

Sanofi (SAN.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
89.00-1.60 (-1.77%)
At close: 05:38PM CET
Full screen
Previous close90.60
Open91.25
Bid0.00 x 0
Ask0.00 x 0
Day's range88.52 - 91.50
52-week range76.45 - 106.66
Volume1,950,364
Avg. volume1,916,731
Market cap113.533B
Beta (5Y monthly)0.42
PE ratio (TTM)17.45
EPS (TTM)5.10
Earnings date28 Oct 2022
Forward dividend & yield3.33 (3.90%)
Ex-dividend date06 May 2022
1y target est99.20
  • Motley Fool

    These 3 Stocks Escaped Tuesday's Market Downdraft

    Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.

  • Financial Times

    GSK and Sanofi shares surge after Zantac ruling victory

    Shares in GSK, Sanofi and Haleon soared on Wednesday as investors welcomed a victory in a legal case relating to a popular heartburn medication that had hung over the companies for months. US district judge Robin Rosenberg in Florida on Tuesday dismissed thousands of lawsuits claiming that the drug Zantac causes cancer. The ruling was a significant win for the pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim.

  • Motley Fool

    Why Shares of Provention Bio Went Up 30.3% in November

    Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence. The pharmaceutical company closed out October at $6.94 and opened November at $7. The move up can be directly tied to the approval of Provention therapy Tzield (teplizumab-mzwv) by the Food and Drug Administration (FDA) on Nov. 17.